These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 25310105

  • 1. Polymorphism of the SRD5A2 gene and the risk of prostate cancer.
    Dušenka R, Tomaškin R, Kliment J, Dobrota D, Dušenková S, Vilčková M, Sivoňová MK.
    Mol Med Rep; 2014 Dec; 10(6):3151-6. PubMed ID: 25310105
    [Abstract] [Full Text] [Related]

  • 2. [V89L polymorphism of the testosterone 5-alpha-reductase II gene and prognostic factors of prostate cancer].
    Tong M, Jin YY, Li G, Liu SM, Ji CD.
    Zhonghua Nan Ke Xue; 2010 Nov; 16(11):990-3. PubMed ID: 21218640
    [Abstract] [Full Text] [Related]

  • 3. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
    Hsing AW, Chen C, Chokkalingam AP, Gao YT, Dightman DA, Nguyen HT, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Reichardt JK.
    Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.
    Lamharzi N, Johnson MM, Goodman G, Etzioni R, Weiss NS, Dightman DA, Barnett M, DiTommaso D, Chen C.
    Int J Cancer; 2003 Jul 01; 105(4):480-3. PubMed ID: 12712437
    [Abstract] [Full Text] [Related]

  • 7. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
    Li X, Huang Y, Fu X, Chen C, Zhang D, Yan L, Xie Y, Mao Y, Li Y.
    Mutagenesis; 2011 May 01; 26(3):371-83. PubMed ID: 21177315
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men.
    Torkko KC, van Bokhoven A, Mai P, Beuten J, Balic I, Byers TE, Hokanson JE, Norris JM, Barón AE, Lucia MS, Thompson IM, Leach RJ.
    Clin Cancer Res; 2008 May 15; 14(10):3223-9. PubMed ID: 18483391
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
    Allen NE, Forrest MS, Key TJ.
    Cancer Epidemiol Biomarkers Prev; 2001 Mar 15; 10(3):185-9. PubMed ID: 11303586
    [Abstract] [Full Text] [Related]

  • 12. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.
    Neslund-Dudas C, Bock CH, Monaghan K, Nock NL, Yang JJ, Rundle A, Tang D, Rybicki BA.
    Prostate; 2007 Nov 01; 67(15):1654-63. PubMed ID: 17823934
    [Abstract] [Full Text] [Related]

  • 13. SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis.
    Wang C, Tao W, Chen Q, Hu H, Wen XY, Han R.
    Prostate; 2010 Feb 01; 70(2):170-8. PubMed ID: 19760631
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer.
    Lévesque É, Laverdière I, Lacombe L, Caron P, Rouleau M, Turcotte V, Têtu B, Fradet Y, Guillemette C.
    Clin Cancer Res; 2014 Feb 01; 20(3):576-84. PubMed ID: 24277450
    [Abstract] [Full Text] [Related]

  • 16. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.
    Cicek MS, Conti DV, Curran A, Neville PJ, Paris PL, Casey G, Witte JS.
    Prostate; 2004 Apr 01; 59(1):69-76. PubMed ID: 14991867
    [Abstract] [Full Text] [Related]

  • 17. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men.
    Allen NE, Reichardt JK, Nguyen H, Key TJ.
    Cancer Epidemiol Biomarkers Prev; 2003 Jun 01; 12(6):578-81. PubMed ID: 12815006
    [Abstract] [Full Text] [Related]

  • 18. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
    Yamada Y, Watanabe M, Murata M, Yamanaka M, Kubota Y, Ito H, Katoh T, Kawamura J, Yatani R, Shiraishi T.
    Int J Cancer; 2001 Jun 01; 92(5):683-6. PubMed ID: 11340572
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Genetic polymorphisms of 17 β-hydroxysteroid dehydrogenase 3 and the risk of hypospadias.
    Sata F, Kurahashi N, Ban S, Moriya K, Tanaka KD, Ishizuka M, Nakao H, Yahata Y, Imai H, Kakizaki H, Nonomura K, Kishi R.
    J Sex Med; 2010 Aug 01; 7(8):2729-38. PubMed ID: 20059664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.